<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pituitary</journal-id><journal-id journal-id-type="iso-abbrev">Pituitary</journal-id><journal-title-group><journal-title>Pituitary</journal-title></journal-title-group><issn pub-type="ppub">1386-341X</issn><issn pub-type="epub">1573-7403</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25566750</article-id><article-id pub-id-type="pmc">4643589</article-id><article-id pub-id-type="publisher-id">628</article-id><article-id pub-id-type="doi">10.1007/s11102-014-0628-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25&#x000a0;months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sheppard</surname><given-names>Michael</given-names></name><address><email>m.c.sheppard@bham.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bronstein</surname><given-names>Marcello D.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Freda</surname><given-names>Pamela</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Serri</surname><given-names>Omar</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>De Marinis</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Naves</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Rozhinskaya</surname><given-names>Liudmila</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Hermosillo Res&#x000e9;ndiz</surname><given-names>Karina</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Ruffin</surname><given-names>Matthieu</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>YinMiao</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Colao</surname><given-names>Annamaria</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><aff id="Aff1"><label/>Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, B15 2TT UK </aff><aff id="Aff2"><label/>Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of S&#x000e3;o Paulo Medical School, S&#x000e3;o Paulo, Brazil </aff><aff id="Aff3"><label/>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY USA </aff><aff id="Aff4"><label/>Service of Endocrinology, Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al, Notre-Dame Hospital, University of Montreal, Montreal, Canada </aff><aff id="Aff5"><label/>Section of Endocrinology, Department of Internal Medicine, Universit&#x000e0; Cattolica del Sacro Cuore, Rome, Italy </aff><aff id="Aff6"><label/>Unit of Endocrinology, Department of Internal Medicine, University of Brasilia, Brasilia, Brazil </aff><aff id="Aff7"><label/>Endocrinology Research Center, Moscow, Russia </aff><aff id="Aff8"><label/>Clinical Development, Novartis Pharmaceuticals Corporation, Florham Park, NJ USA </aff><aff id="Aff9"><label/>Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland </aff><aff id="Aff10"><label/>Novartis Pharmaceuticals Corporation, East Hanover, NJ USA </aff><aff id="Aff11"><label/>Dipartimento di Medicina Clinica e Chirurgia, Universit&#x000e0; Federico II di Napoli, Naples, Italy </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>18</volume><issue>3</issue><fpage>395</fpage><lpage>396</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media New York 2015</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e87" ext-link-type="doi" xlink:href="10.1007/s11102-014-0585-6"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media New York 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Pituitary DOI 10.1007/s11102-014-0585-6</title><p>An error appears twice in the published article: in the first row, second column of Tables&#x000a0;<xref rid="Tab1" ref-type="table">4</xref> and <xref rid="Tab2" ref-type="table">5</xref>. Both columns were labelled: Extension baseline. The authors would like to note that this text is incorrect; both column labels have been corrected to: Core baseline.<table-wrap id="Tab1"><label>Table&#x000a0;4</label><caption><p>Overall shift in glucose from core baseline to last available value up to month 26</p></caption><graphic xlink:href="11102_2014_628_Tab4_HTML" id="MO1"/><table-wrap-foot><p>Shaded boxes represent the patients with a shift in glucose level (mg/dL) that indicates a worse diabetic status at the last reported value compared with core baseline</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;5</label><caption><p>Overall shift in HbA<sub>1c</sub> from core baseline to last available value up to month 26</p></caption><graphic xlink:href="11102_2014_628_Tab5_HTML" id="MO2"/><table-wrap-foot><p>Shaded boxes represent the patients with a shift in HbA<sub>1c</sub> level (%) that indicates a worse diabetic status at the last reported value compared with core baseline</p></table-wrap-foot></table-wrap></p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s11102-014-0585-6.</p></fn></fn-group></back></article>